MAPT and Alzheimer disease: Secondary outcomes are biomarkers of AD pathology and neurodegeneration (Aβ42, Aβ40, p‐tau217, p‐tau181, BD‐tau, GFAP, NfL) and growth factors (BDNF, IGF‐1), measured through blood samples collected at pre‐ and post‐condition (at 3, 50, 70 min).